Publicacións nas que colabora con José Garnacho Montero (29)

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  2. Use of hospital resources in ICU inpatients with infections caused by carbapenem-resistant Gram-negative bacteria: A real clinical practice-based study in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 162-168

2022

  1. A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 455-467

  2. Impact of one year of pandemic on Spanish Intensive Care Units

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 4, pp. 392-400

  3. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  4. Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study

    The Lancet Regional Health - Europe, Vol. 18

  5. Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units

    Medicina Intensiva, Vol. 46, Núm. 2, pp. 81-89

2021

  1. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care

  2. Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study

    Medicina Intensiva, Vol. 45, Núm. 6, pp. 332-346

  3. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Critical Care, Vol. 25, Núm. 1

2019

  1. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial

    Critical Care, Vol. 23, Núm. 1

2018

  1. Application of BioFire FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia

    Clinical Microbiology and Infection, Vol. 24, Núm. 11, pp. 1213.e1-1213.e4

  2. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

    Intensive Care Medicine, Vol. 44, Núm. 9, pp. 1470-1482

  3. Improved empirical antibiotic treatment of sepsis after an educational intervention: The ABISS-Edusepsis study

    Critical Care, Vol. 22, Núm. 1

2017

  1. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme

    PLoS ONE, Vol. 12, Núm. 3

  2. Response to bile salts in clinical strains of Acinetobacter baumannii lacking the adeABC efflux pump: Virulence associated with quorum sensing

    Frontiers in Cellular and Infection Microbiology, Vol. 7, Núm. MAY

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

2015

  1. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: Study protocol for a randomized controlled trial

    Trials, Vol. 16, Núm. 1

2014

  1. Epidemiologic and clinical impact of acinetobacter baumannii colonization and infection: A reappraisal

    Medicine (United States), Vol. 93, Núm. 5, pp. 202-210

  2. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: A Spanish cohort study

    Intensive Care Medicine, Vol. 40, Núm. 4, pp. 572-581